becton dickinson compani
usd pm et
summari compani provid wide rang medic devic diagnost product use
hospit doctor offic research lab set
price-to-earnings oper ep
market competit new product
introduct rival potenti significantli
affect market dynam chang domest foreign
health care industri practic regul may result
increas price pressur lower reimburs
product still product line
favor demand price characterist
medic equip industri gener
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
compani lower
target price base multipl
ep
sep-q ep vs fell short
estim lower fy sep
initi fy
ep sep-q sale grew
organ billion slightli
expect excit fiscal year
adjust oper margin
full year margin margin expans
primarili driven realiz bard
synergi expect drive basi
point margin expans fy
revenu growth china fell short
expect constant currenc vs
full year metric fell short
expect due price pressur
basic medic devic initi
guidanc fy ep
origin expect like
continu currenc headwind
chines price pressur fy
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
becton dickinson compani
corpor overview becton dickinson compani global medic technolog compani
engag develop manufactur sale broad rang medic suppli devic
laboratori equip diagnost product use healthcar institut life scienc research
clinic laboratori pharmaceut industri gener public one first
compani sell -made glass syring pioneer product hypoderm needl
tradit two busi segment bd medic bd life scienc decemb
acquisit bard bcr compani began report third segment bd
fiscal year end septemb gener billion revenu break-out
billion medic segment billion life scienc billion
intervent
bd medic segment produc broad array medic technolog devic use help
improv healthcar deliveri wide rang set primari custom serv bd medic
hospit clinic physician offic practic consum retail pharmaci government
nonprofit public health agenc pharmaceut compani healthcar worker organiz
unit segment diabet care medic deliveri solut medic manag solut
pharmaceut system exampl product includ syring pen needl intraven cathet
medic deliveri infus therapi deliveri system pre-fil drug deliveri system
bd life scienc segment provid product safe collect transport diagnost
specimen instrument reagent system detect broad rang infecti diseas
healthcare-associ infect cancer addit bd life scienc produc research clinic
tool facilit studi cell compon cell gain better understand
normal diseas process inform use aid discoveri develop new
drug vaccin improv diagnosi manag diseas primari custom
serv segment hospit laboratori clinic blood bank healthcar worker public
health agenc physician offic practic academ govern institut pharmaceut
biotechnolog compani organiz unit segment preanalyt system
diagnost system bioscienc
bd intervent segment includ major formerli bard product offer
certain product offer formerli report medic segment intervent
segment broken three organiz unit surgeri peripher intervent urolog critic
care unit includ product hernia soft tissu repair biolog graft cathet drug
coat balloon cancer diagnost
impact major develop decemb close acquisit bard inc bcr
total enterpris valu billion bcr lead develop manufactur market
medic technolog field vascular urolog oncolog surgic specialti acquisit
substanti chang product mix bcr product faster grow clinic area
deal also boost alreadi sizeabl presenc china acquisit
start report new segment bd intervent includ major bcr product
offer integr probabl difficult given scale adjust organiz
design design integr plan
last sizeabl acquisit prior bcr carefus cfn march acquir cfn
lead provid medic devic diagnost product billion acquisit
departur histori bolt-on acquisit integr larg complet may
three year acquisit
financi trend fiscal year end septemb revenu expand
year-over-year billion larg bcr acquisit five-year cumul annual
growth rate compound-annual-growth-rate five-year compound-annual-growth-rate normal ep fy normal
ep vs prior year period
decemb net debt total capit ratio leverag ratio net debt
ebitda debt elev rel histor level primarili bcr
acquisit commit de-lever within three year compani indic
could pay debt quicker leav flexibl opportunist tuck-in
execut vice-president research
 develop
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
base cfra proprietari quantit model
stock rank overvalu
figur base fiscal year-end price
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc octob technic indic
neutral
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fundament outlook health care
equip sub-industri next month
neutral continu expect compani
sub-industri achiev robust organ
growth posit macroeconom environ
compani gener benefit new
product launch laxer food drug
administr fda technolog advanc
sub-industri also mani product area
histor recession-resist
equip use non-elect procedur
howev valuat health care equip
compani elev rel
composit suggest posit
fundament reflect share
think higher valuat
sub-industri mostli warrant
strong recent margin expans revenu
growth associ robust product
expect sub-industri earn rise
high-single-digit percentag driven
continu pipelin innov new product
emerg market expans speed
new product come market
increas recent year
success effort fda reduc
approv time medic devic
time see price pressur incess
headwind medic equip compani
impact china-u trade war appear
insignific far medic
equip compani especi sinc
base medic equip manufactur
sourc insignific amount product
input china addit
chines govern seek lower health
care cost provid better health care
insul medic equip
sub-industri mount trade tension
larg medic equip target
chines tariff mean certain
compani
like
hurt trade tension howev bigger
concern medic equip
manufactur potenti trade
tension caus signific slowdown
possibl threat state american
health care system lawsuit texa
rule unconstitut
current expect upheld upon
appeal although decis could take
coupl year reach democrat
took control hous repres
period think
see substanti effort
republican trump administr
tri repeal
anoth legisl issu could impact
medic equip manufactur
potenti return medic devic tax
medic devic tax suspend
end congress fail
repeal suspend tax medic
devic manufactur could significantli
gener see posit long-term
fundament includ increas global
demand cost-effect value-bas
health care age popul rise
outlay result steadi flow
innov product revenu growth
year-to-d septemb
vs increas valu
 composit index
vs declin
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
dickinson compani maintain target
ep estim multipl near
high end five-year rang chang
made product servic portfolio sep-q ep vs
lower estim lower fy sep ep
initi fy ep sep-q sale increas
billion driven acquisit organ basi revenu grew
medic segment grew life scienc intervent
initi adjust ep outlook seem low us
expect late fiscal macroeconom headwind continu rise
resin price unfavor foreign exchang tariff-rel impact lower
gross leverag ratio debt-ebitda septemb
decemb track three-year goal reduc gross leverag
/kevin huang cfa
et cfra keep buy opinion share becton dickinson
compani maintain target
ep estim multipl near high-end
five-year rang slightli peer averag jun-q
ep vs higher estim rais
sep ep jun-q sale increas billion
driven acquisit organ basi revenu grew medic
segment grew life scienc intervent
encourag bard integr activ proceed plan
manag confid achiev million cost synergi
lower gross leverag debt-ebitda
march decemb juli made tuck-in
acquisit tva medic compani develop minimally-invas
solut patient chronic kidney diseas think
technolog could signific opportun /kevin huang cfa
analyst research note compani news
pm et cfra maintain buy opinion share becton dickinson
compani lower target price base
multipl ep sep-q ep vs
fell short estim lower fy sep
initi fy ep sep-q sale grew
organ billion slightli expect excit
fiscal year adjust oper margin full year margin
margin expans primarili driven realiz bard
synergi expect drive basi point margin expans
fy revenu growth china fell short expect
constant currenc vs full year metric fell short
expect due price pressur basic medic devic
initi guidanc fy ep
origin expect like continu currenc headwind
chines price pressur fy /kevin huang cfa
pm et cfra reiter buy opinion share becton dickinson
compani keep target below-p
multipl ep estim jun-q ep
vs surpass consensu maintain fy sep ep
lower fy ep jun-q sale grew
billion continu face strong currenc headwind
howev expect headwind abat go forward organ basi
revenu grew led growth medic segment follow
life scienc intervent despit unresolv trade
tension sale china grew organ confid tariff
environ hurt busi china look toward fy
forecast least earn growth continu core revenu growth
also expect fda provid posit updat soon usag
drug paclitaxel regard previously-rais concern increas mortal
risk associ drug /kevin huang cfa
pm et cfra keep buy opinion share becton dickinson
compani maintain target base
ep estim mar-q ep vs
in-lin consensu expect lower sep ep
maintain ep mar-q sale decreas
billion neg impact strong dollar
worse-than-expect organ basi revenu grew led
growth medic segment follow intervent
life scienc emerg market growth remain strong quarter
bard integr synergi remain track expect compani lower
full-year earn outlook due fda warn march regard
increas mortal risk associ pacliataxel-co devic
drug-coat balloon dcb anticip reduct dcb sale
creat basi point headwind ep growth expect fda updat
june key catalyst /kevin huang cfa
pm et cfra maintain buy opinion share becton dickinson
compani lift target
ep estim multipl near high-end
five-year rang substanti chang
made recent year product servic portfolio dec-q
ep vs lower estim lower
sep ep reduc ep
dec-q sale increas billion driven acquisit
organ basi revenu grew medic segment grew life
scienc intervent expect currenc
signific headwind forecast ep increas
strongest impact occur march quarter also expect
realiz anoth million cost synergi relat bard
acquisit track origin expect /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
becton dickinson compani
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
becton dickinson compani
